About The Clinx
About The Clinx
A place for Clinicians and Healthcare Suppliers to share knowledge and learn more about THE CLINICIAN E
IN THE NEWS
: Fri, 20 Apr 2018 15:32:24 EDT
Read clinically focused news coverage of key developments from AGS 2018.
Medscape Internal Medicine
Real-World Data Back Coronary Sinus Stent in Refractory Angina
: Fri, 20 Apr 2018 14:51:28 EDT
About 80% of patients with chronic, refractory angina appear to respond to the novel stent, but its path to US approval is unsettled.
Medscape Medical News
Drug Test Spurs Frank Talk Between Hypertension Patients and Doctors
: Fri, 20 Apr 2018 14:38:23 EDT
Roughly half of patients don’t take their high blood pressure medicine as they should, even though heart disease is the leading cause of death in America. Now, a drug test can flag whether a patient is taking the prescribed medication and is meant to spark a more truthful conversation between patient and doctor.
Kaiser Health News
Apr 20, 2018 This Week in Cardiology
: Fri, 20 Apr 2018 12:52:36 EDT
Ambulatory BP measurements, advanced practice providers, medical marijuana for sleep apnea, Barbara Bush's comfort care, and apixaban for cardioversion are the topics discussed in this week's podcast.
theheart.org on Medscape
Displaying results 5-8 (of 20)
HEALTHCARE SUPPLIER NEWS
Fierce Medical Devices
FDA ‘conflicted’ on Lilly and Incyte’s refiled baricitinib
: Fri, 20 Apr 2018 09:18:30 +0000
Eli Lilly and Incyte’s second attempt to get U.S. approval of rheumatoid arthritis drug baricitinib could be scuppered again by lingering FDA concerns about safety.
MorphoSys supersizes IPO, bagging $208M for cancer R&D
: Fri, 20 Apr 2018 09:06:42 +0000
MorphoSys has supersized its IPO, pulling in $208 million to develop its anti-CD19 antibody MOR208. The dialed-up IPO haul gives MorphoSys a $500 million-plus war chest to crash the CAR-T party with a drug it thinks provides safer, more durable efficacy without the cost or complexity of cell therapies.
After questioning Lilly/Incyte's baricitinib, FDA director jumps ship to AstraZeneca
: Thu, 19 Apr 2018 21:02:34 +0000
The FDA’s Badrul Chowdhury is moving to AstraZeneca in the same week that he made a series of critical marks against Eli Lilly and Incyte's long-delayed baricitinib, which is set for an advisory committee on Monday.
Grail to seek an additional $1B in funding before Hong Kong IPO, report says
: Thu, 19 Apr 2018 15:03:24 +0000
Cancer blood test developer Grail is reportedly considering whether to squeeze in yet another billion-dollar funding round before it goes public in Hong Kong later this year, according to Bloomberg.
Displaying results 5-8 (of 25)
HEALTHCARE SUPPLIERS INFO
ABOUT THE CLINX
Clinician Owned and Veteran Owned
copyright 2017 THE CLINICIAN EXCHANGE.
Olark live chat software